JP2022525121A - Ｐａｓｋの阻害剤としてのピラゾロピリジン誘導体 - Google Patents

Ｐａｓｋの阻害剤としてのピラゾロピリジン誘導体 Download PDF

Info

Publication number
JP2022525121A
JP2022525121A JP2021555034A JP2021555034A JP2022525121A JP 2022525121 A JP2022525121 A JP 2022525121A JP 2021555034 A JP2021555034 A JP 2021555034A JP 2021555034 A JP2021555034 A JP 2021555034A JP 2022525121 A JP2022525121 A JP 2022525121A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pyrazolo
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525121A5 (https=
Inventor
ニコラス アラン ビューモント ステファン
マリー ボック ザビエール
コマス マルティネス ダニエル
マリー ジャンクール アグネス
ギルバート ラベグエレ フレデリック
ロペズ ラモス ミリアム
テマル‐ライブ タオウエス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2022525121A publication Critical patent/JP2022525121A/ja
Publication of JP2022525121A5 publication Critical patent/JP2022525121A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021555034A 2019-02-25 2020-02-17 Ｐａｓｋの阻害剤としてのピラゾロピリジン誘導体 Pending JP2022525121A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902490.0 2019-02-25
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2020/054122 WO2020173739A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Publications (2)

Publication Number Publication Date
JP2022525121A true JP2022525121A (ja) 2022-05-11
JP2022525121A5 JP2022525121A5 (https=) 2023-02-20

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555034A Pending JP2022525121A (ja) 2019-02-25 2020-02-17 Ｐａｓｋの阻害剤としてのピラゾロピリジン誘導体

Country Status (19)

Country Link
US (1) US20220144823A1 (https=)
EP (1) EP3931191B1 (https=)
JP (1) JP2022525121A (https=)
KR (1) KR20210134001A (https=)
CN (1) CN113474344A (https=)
AR (1) AR124749A1 (https=)
AU (1) AU2020229041A1 (https=)
BR (1) BR112021016642A2 (https=)
CA (1) CA3130154A1 (https=)
CO (1) CO2021010485A2 (https=)
ES (1) ES2963409T3 (https=)
GB (1) GB201902490D0 (https=)
IL (1) IL285751A (https=)
MA (1) MA55074A (https=)
MX (1) MX2021010093A (https=)
PH (1) PH12021552032A1 (https=)
SG (1) SG11202109157TA (https=)
TW (1) TW202045505A (https=)
WO (1) WO2020173739A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
JP2017537922A (ja) * 2014-12-02 2017-12-21 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロ［１，５−ａ］ピリジンおよびイミダゾ［１，２−ａ］ピラジンならびにそれらの使用
WO2018200855A1 (en) * 2017-04-27 2018-11-01 The Brigham And Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
JP2017537922A (ja) * 2014-12-02 2017-12-21 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロ［１，５−ａ］ピリジンおよびイミダゾ［１，２−ａ］ピラジンならびにそれらの使用
WO2018200855A1 (en) * 2017-04-27 2018-11-01 The Brigham And Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAN-DAN ZHANG ET AL.: "Per-Arnt-Sim Kinase (PASK): An Emerging Regulator of Mammalian Glucose and Lipid Metabolism", NUTRIENTS, vol. 7, no. 9, JPN7024000164, 2015, pages 7437 - 7450, ISSN: 0005243548 *
XIAOYING WU ET AL.: "PAS Kinase Drives Lipogenesis through SREBP-1 Maturation", CELL REPORTS, vol. 8, no. 1, JPN7024000163, 2014, pages 242 - 255, ISSN: 0005243547 *

Also Published As

Publication number Publication date
CA3130154A1 (en) 2020-09-03
TW202045505A (zh) 2020-12-16
SG11202109157TA (en) 2021-09-29
MA55074A (fr) 2022-01-05
ES2963409T3 (es) 2024-03-27
MX2021010093A (es) 2021-09-21
BR112021016642A2 (pt) 2021-11-03
KR20210134001A (ko) 2021-11-08
IL285751A (en) 2021-10-31
US20220144823A1 (en) 2022-05-12
PH12021552032A1 (en) 2022-11-14
AU2020229041A1 (en) 2021-10-21
WO2020173739A1 (en) 2020-09-03
EP3931191A1 (en) 2022-01-05
GB201902490D0 (en) 2019-04-10
CN113474344A (zh) 2021-10-01
EP3931191B1 (en) 2023-10-04
CO2021010485A2 (es) 2021-08-19
AR124749A1 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
JP7337883B2 (ja) 乳酸脱水素酵素の小分子阻害剤及びその使用方法
KR102824962B1 (ko) 헤테로시클릭 rip1 억제 화합물
JP6997462B2 (ja) がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物
JP6858984B2 (ja) がんおよび糖尿病の治療に有用な６−ヘテロシクリル−４−モルホリン−４−イルピリジン−２−オン化合物
CN109890827A (zh) 螺环化合物
BR112017024618B1 (pt) Compostos agonistas de triazol do receptor apj, composições e usos relacionados
TW202143954A (zh) 三環性螺化合物之用途
CN114456159A (zh) 氮取代杂环噻吩类化合物及其用途
WO2017133681A1 (zh) 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途
JP2019523237A (ja) 乳酸脱水素酵素の阻害剤としての１ｈ−ピラゾール−１−イル−チアゾールおよびそれらの使用方法
CN119039290A (zh) P2x3调节剂
CN108883122A (zh) 有用于治疗疾病的c-糖苷化合物
WO2020043173A1 (zh) 作为受体相互作用蛋白1(rip1)激酶抑制剂的杂环化合物
CN113906020A (zh) 用于治疗皮肤病的缓激肽（bk）b2受体拮抗剂的(r)-3-(氯-5-氟-2-((4-(1h-吡唑-1-基)-2-甲基喹啉-8-基氧基)甲基)苯基）吗啉衍生物及相关的化合物
EP3704112A1 (en) Alkene spirocyclic compounds as farnesoid x receptor modulators
EP4562015A2 (en) Cdk2 inhibitors and methods of using the same
CN112689630A (zh) 具有双环核部分的新型lxr调节剂
WO2024026484A2 (en) Cdk2 inhibitors and methods of using the same
JP2022525121A (ja) Ｐａｓｋの阻害剤としてのピラゾロピリジン誘導体
TW201912161A (zh) 嗎啉基吡啶酮化合物
KR20150082301A (ko) 2-피리돈 화합물
WO2023125486A1 (zh) 生长抑素受体5拮抗剂及其药物组合物及用途
BR112021015930A2 (pt) Compostos de amida substituídos úteis como moduladores de receptor farnesoide x
JP2021522165A (ja) ２，６−ジアミノ−３，４−ジヒドロピリミジン−４−オン誘導体および治療におけるその使用
CA3015045C (en) 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240813